New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:11 EDTBMRNBioMarin says BMN 165-302 study to be available in Q4 of 2015
BioMarin announced last night that it intends to modify the entry criteria for the BMN 165-302 randomized discontinuation study. "The purpose of the eligibility modification is to leverage those patients who have relatively weaker immune reactions to PEG PAL, who therefore achieve Phe reductions faster, at relatively lower doses and with relatively fewer side effects. Under the revised entry criteria, patients will need to demonstrate a pre-specified reduction in blood Phe from PEG PAL during the BMN 165-301 feeder study prior to entering the BMN 165-302 RDT study," it stated. Based on the changed BMN 165-302 protocol, associated review of the proposed protocol and preliminary BMN 165-301 data with the FDA, and requirement for additional patients, the company now expects data from the enriched BMN 165-302 study to be available in Q4 of 2015.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
18:20 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 31.8% after reporting better than expected second quarter results and guidance above analyst estimates... Aruba Networks (ARUN), up 2.3% after reporting quarterly results and announcing a 3.7% workforce reduction... HEICO (HEI), up 2.3% after raising fiscal 2014 net income guidance. ALSO HIGHER: Chemtura (CHMT) and Diebold (DBD) are both up marginally after Mario Gabelli commented on the companies in an interview with CNBC. DOWN AFTER EARNINGS: Smith & Wesson (SWHC), down 10.2% after reporting disappointing first quarter results and lowering fiscal 2014 outlook. ALSO LOWER: Sturm, Ruger (RGR), down 4% after Smith & Wesson reported quarterly results... BioMarin (BMRN), down 1.35 after lowering fiscal 2014 revenue guidance.
16:36 EDTBMRNBioMarin lowers FY14 revenue view to $680M-$700M from $745M-$765M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use